ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005052

irritable bowel syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. irritable bowel syndrome. Diseases, record MONDO_0005052. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005052

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
irritable bowel syndrome
Open Targets
Open Targets ID
MONDO_0005052
Open Targets
Other names
Adaptive colitis, Colitides, Mucous, Colitis, Mucous, Colon spasm, Colon, Irritable, Functional bowel disease, IBD, IBS, IBS - Irritable bowel syndrome, IC - Irritable colon, Irritable Bowel Syndromes, Irritable bowel, Irritable bowel - IBS, Irritable colon (disorder), Irritable colon - Irritable bowel syndrome, Irritable colon syndrome, Membranous colitis, Mucous Colitides, Mucous colitis, Nervous colitis, Psychogenic IBS, Spastic colitis, Syndrome, Irritable Bowel, Syndromes, Irritable Bowel, [X]Psychogenic IBS, irritable colon, mucus colitis, spastic colon
Open Targets
Disease Ontology
DOID:9778
Disease Ontology
MeSH
D043183
MeSH
NCI Thesaurus
C82343
NCI Thesaurus
Highest stage of its drugs
Approval, for 23 of its 113 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs113

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
LINACLOTIDECHEMBL3301675ProteinApprovalDailyMed, EMA Human Drugs, PMDA and TTD1499Drugs and targets
LUBIPROSTONECHEMBL1201134Small moleculeApprovalDailyMed933Drugs and targets
ALOSETRONCHEMBL1110Small moleculeApprovalTTD433Drugs and targets
ELUXADOLINECHEMBL2159122Small moleculeApprovalDailyMed422Drugs and targets
TEGASERODCHEMBL76370Small moleculeApprovalTTD422Drugs and targets
PRUCALOPRIDECHEMBL117287Small moleculeApprovalTTD322Drugs and targets
TRIMEBUTINECHEMBL190044Small moleculeApprovalTTD322Drugs and targets
CHARCOAL, ACTIVATEDCHEMBL2106049Small moleculeApprovalTTD211Drugs and targets
MEBEVERINECHEMBL282121Small moleculeApprovalTTD211Drugs and targets
PLECANATIDECHEMBL2103867ProteinApprovalTTD211Drugs and targets

1 to 10 of 113

See all 113 drugs

Targets118

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
HTR3A5-hydroxytryptamine receptor 3A7Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3 (5-HT3) receptor partial agonist; Serotonin 3a (5-HT3a) receptor antagonistApprovalhttps://conductscience.org/library/genes/3359Drugs and targets
SLC6A2Sodium-dependent noradrenaline transporter6Norepinephrine transporter inhibitorPhase 3https://conductscience.org/library/genes/6530Drugs and targets
SLC6A4Sodium-dependent serotonin transporter6Serotonin transporter inhibitorPhase 2/3https://conductscience.org/library/genes/6532Drugs and targets
HTR3BSerotonin 3 (5-HT3) receptor5Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3 (5-HT3) receptor partial agonistApprovalhttps://conductscience.org/library/genes/9177Drugs and targets
HTR45-hydroxytryptamine receptor 45Serotonin 4 (5-HT4) receptor agonist; Serotonin 4 (5-HT4) receptor partial agonistApprovalhttps://conductscience.org/library/genes/3360Drugs and targets
OPRM1Mu-type opioid receptor5Mu opioid receptor agonist; Mu opioid receptor partial agonist; Opioid receptors; mu/kappa/delta antagonistApprovalhttps://conductscience.org/library/genes/4988Drugs and targets
HTR3CSerotonin 3 (5-HT3) receptor4Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3 (5-HT3) receptor partial agonistApprovalhttps://conductscience.org/library/genes/170572Drugs and targets
HTR3DSerotonin 3 (5-HT3) receptor4Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3 (5-HT3) receptor partial agonistApprovalhttps://conductscience.org/library/genes/200909Drugs and targets
HTR3ESerotonin 3 (5-HT3) receptor4Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3 (5-HT3) receptor partial agonistApprovalhttps://conductscience.org/library/genes/285242Drugs and targets
OPRK1Kappa-type opioid receptor3Kappa opioid receptor agonist; Kappa opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonistPhase 3https://conductscience.org/library/genes/4986Drugs and targets

1 to 10 of 118

See all 118 targets

Trials126

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01543178Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment StudyPhase 32,5832015-07-08Irritable Bowel Syndrome With DiarrheaRIFAXIMINOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00730171An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationPhase 31,7432018-02-19Irritable Bowel Syndrome With Constipation, Chronic ConstipationLINACLOTIDEOpen Targets' reading of its recordClinicalTrials.gov
NCT00765999An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationPhase 31,5592019-02-15Chronic Constipation, Irritable Bowel Syndrome With ConstipationLINACLOTIDEOpen Targets' reading of its recordClinicalTrials.gov
NCT02590432
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Phase 48282019-08-22Irritable Bowel Syndrome With Constipation, Chronic Idiopathic ConstipationLINACLOTIDEOpen Targets' reading of its recordClinicalTrials.gov
NCT00938717Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Phase 38052013-01-30Irritable Bowel Syndrome With ConstipationLINACLOTIDEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT02559206Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)Phase 27592020-04-24Irritable Bowel Syndrome With ConstipationLINACLOTIDEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00724126Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)Phase 36372014-07-28Non-Constipation Irritable Bowel SyndromeRIFAXIMINIts record names the diseaseClinicalTrials.gov
NCT00380250Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With ConstipationPhase 35902014-02-11Irritable Bowel Syndrome With ConstipationLUBIPROSTONEOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT00761007Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)Phase 25542010-10-01Irritable Bowel SyndromeIBODUTANTIts record names the diseaseClinicalTrials.gov
NCT0210719612-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)Phase 35352016-09-27Irritable Bowel Syndrome With DiarrheaIBODUTANTOpen Targets' reading of its recordClinicalTrials.gov

1 to 10 of 126

See all 126 trials

Comparisons in its trials50

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Linaclotide (CC) vs Linaclotide (IBS-C): Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs)399 of 523748 of 1,0321,555NCT00765999Trial comparisons
Linaclotide (CC) vs Linaclotide (IBS-C): serious adverse events31 of 52357 of 1,0321,555NCT00765999Trial comparisons
LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): deaths from any cause1 of 5080 of 318826NCT02590432Trial comparisons
LINZESS® 145 μg (CIC) vs LINZESS® 290 μg (IBS-C): serious adverse events16 of 5086 of 318826NCT02590432Trial comparisons
LINZESS® 145 μg (CIC, Open Label) vs LINZESS® 290 μg (IBS-C, Open Label): Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in Serum3 of 4981 of 309807NCT02590432Trial comparisons
Linaclotide vs Placebo: serious adverse events4 of 4027 of 403805NCT00938717Trial comparisons
Linaclotide vs Placebo: Abdominal Pain Responder, 9 Out of 12 Weeks156 of 40179 of 403804NCT00938717Trial comparisons
Linaclotide vs Placebo: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks135 of 40156 of 403804NCT00938717Trial comparisons
Linaclotide vs Placebo: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks51 of 40112 of 403804NCT00938717Trial comparisons
Linaclotide vs Placebo: Abdominal Pain Responder for 6 Out of 12 Weeks196 of 401139 of 403804NCT00938717Trial comparisons

1 to 10 of 50

See all 50 comparisons in its trials

Papers from its trials58

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
41505133RESULT1PubMed
28408193RESULT1PubMed
27144617RESULT1PubMed
26044145RESULT1PubMed
24943480RESULT1PubMed
23731747RESULT1PubMed
22517769RESULT1PubMed
22301931RESULT1PubMed
22288893RESULT1PubMed
21883322RESULT1PubMed

1 to 10 of 58

See all 58 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005052

GET https://conductscience.org/api/diseases/v1/MONDO_0005052/drugs?page=2

API referenceFor AI assistants